Positively Aware Evotaz


ATV/COBI atazanavir/cobicistat

Recommended as a component of initial regimen in certain clinical situations
Protease Inhibitor

Standard Dose

One tablet once daily with food. Each tablet contains 300 mg of atazanavir boosted by 150 mg cobicistat. Must be taken in combination with another antiretroviral(s) which does not contain the medications in this drug or medication from the same drug classes. Use with Intelence or Sustiva is not recommended. See “More information” for pediatric dose update.

Use in treatment-experienced patients depends on protease inhibitor drug resistance. Co-administration with drugs containing tenofovir disoproxil fumarate (Viread, found in Atripla, Cimduo, Complera, Delstrigo, Stribild, Symfi, Symfi Lo, Temixys, and Truvada) is not recommended if kidney function as measured by creatinine clearance is below 70 mL/min. Co-administration with drugs containing tenofovir alafenamide (TAF, found in Biktarvy, Descovy, Genvoya, Odefsey, and Symtuza, and under the brnad name Vemlidy) is not recommended if kidney function as measured by creatinine clearance is below 30 mL/min.

Not recommended for people with any degree of liver impairment or those who are treatment-experienced and on hemodialysis.

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Evotaz is not recommended during pregnancy due to substantially lower exposures of atazanavir and cobicistat during pregnancy.
  • See the individual drugs contained in Evotaz: Reyataz and Tybost.
  • See package insert for more complete information on potential side effects and interactions.


Bristol-Myers Squibb
evotaz.com; (800) 321-1335



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments